HP yeast gene | Human ortholog | Apoptotic phenotype (% dead cells) of yeast heterozygous deletion mutants treated with MMS. (Change in rate of apoptosis, relative to WT, is significant at p < 0.05 for all yeast heterozygotes.) | Mammalian apoptosis-related phenotype from literature | |
---|---|---|---|---|
 |  | 0.01% MMS | 0.001% MMS |  |
WT | - | 79% | 68% | Â |
CTF8 | CHTF8 | 49% | - | - |
MSH2 | MSH2 | 56% | - | RNAi-mediated knockdown decreases apoptosis [25] |
MUS81 | MUS81 | 56% | - | - |
TPD3 | PPP2R1B | 60% | - | RNAi-mediated knockdown decreases apoptosis [26] |
TOP1 | TOP1 | 55% | - | RNAi-mediated knockdown reduces nuclear apoptosis [27] |
RAD54 | RAD54L | 44% | Â | - |
SMC3 | SMC3 | - | 30% | RNAi-mediated knockdown increases apoptosis [28] |
RAD1 | ERCC4 | - | 22% | - |
DNL4 | LIG4 | - | 46% | Extensive apoptosis in mouse deletion homozygotes [29] |
MAD1 | MAD1L1 | - | 20% | - |
MEU1 | MTAP | - | 94% | Pharmacological targeting of MTAP promotes apoptosis [30] |
MLH1 | MLH1 | - | 93% | Abnormal apoptosis (OMIM) |
CHK1 | CHEK1 | - | 82% | Blocking CHK1 induces apoptosis [31] |
UBX4 | ASPSCR1 | - | 80% | Regulator of apoptosis (OMIM) |